Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company, which focuses on the development of innovative medicines to address unmet medical needs. The firm is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. The company uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.
Follow-Up Questions
Poolbeg Pharma PLC のCEOは誰ですか？
Dr. Jeremy Skillington は Poolbeg Pharma PLC の Chief Executive Officer で、2021 から在籍しています。
POLBF の株価パフォーマンスは？
POLBF の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Poolbeg Pharma PLC の主な事業テーマや業界は？
Poolbeg Pharma PLC は Pharmaceuticals 業界、セクターは Health Care に属しています。
